NCT06665113 Neuroprotective Effects of Long-term TaVNS in Early Parkinson's Disease Patients
| NCT ID | NCT06665113 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Kezhong Zhang |
| Condition | Parkinson Disease, Idiopathic |
| Study Type | INTERVENTIONAL |
| Enrollment | 12 participants |
| Start Date | 2024-12-23 |
| Primary Completion | 2026-06 |
Trial Parameters
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
Brief Summary
This study is a randomized, double-blind, controlled trial exploring the effects of long-term taVNS intervention in patients with early-stage Parkinson's disease.
Eligibility Criteria
Inclusion Criteria: 1. Age 55-75 years. 2. Clinically diagnosed Idiopathic Parkinson's disease patients according to the 2016 Chinese diagnostic criteria for Parkinson's disease. 3. Hoehn and Yahr (H\&Y) stage ≤ 2.5 at medication initiation. 4. Parkinson's disease duration ≤ 3 years. 5. Receiving standard anti-Parkinson's disease medication treatment. Exclusion Criteria: 1. Patients with cognitive impairment (MMSE \< 24 and/or MoCA \< 26) or mental illnesses, or those unable to cooperate for other reasons. 2. Use of neuroprotective medications within 90 days prior to baseline, including monoamine oxidase B inhibitors (rasagiline, selegiline), certain dopamine receptor agonists (ropinirole), and GLP-1 receptor agonists such as Exenatide and NLY-01. 3. Use of any medications that may affect dopamine metabolism and/or dopamine receptors within 90 days prior to baseline, including typical and atypical antipsychotics, metoclopramide, α-methyl-dopa, flunarizine, apomorphine, amphetamine deri
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.